ArticleBreast cancer research and treatment2022

Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).

Marc Thill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.